Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16564426 | 0.99 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2L3MBTL1GRM2HTR6 | |
| Acetic Acid SCHEMBL974712 | 0.97 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2L3MBTL1GRM2HTR6 | |
| SCHEMBL52448 | 0.92 | GRM2 (0.44) | L3MBTL1GRM2NAMPTBRD4CREBBP | |
| SCHEMBL12375385 | 0.83 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2HTR6HTR2CSLC6A2 | |
| SCHEMBL2038391 | 0.83 | MEN1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1GRM2CREBBP | |
| SCHEMBL27679076 | 0.82 | DRD4 (0.39) | SMN1; SMN2GRM2NAMPT | |
| SCHEMBL974713 | 0.82 | NAMPT (0.39) | L3MBTL1GRM2NAMPTBRD4CREBBP | |
| SCHEMBL2035123 | 0.81 | HTR2C (0.41) | ALDH1A1SMN1; SMN2HTR6HTR2CSLC6A2 | |
| SCHEMBL2040522 | 0.81 | PTGDR2 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1NAMPTBRD4 | |
| SCHEMBL27893598 | 0.81 | SLC6A2 (0.40) | ALDH1A1SMN1; SMN2L3MBTL1NAMPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483243-B1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2483243-B1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| CN-102574792-B | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI AVENTIS US LLC | 2014-07-09 | — | — | CN | disclosed |
| CN-102574792-B | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI AVENTIS US LLC | 2014-07-09 | — | — | CN | disclosed |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2014-06-12 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| CN-101429194-A | Process for the preparation of tryptase inhibitors | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | CN | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1737848-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | Aventis Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | ALDH1A1 1305/4885SMN1; SMN2 2159/4885L3MBTL1 4850/4885 |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | CMA1, TPSAB1, TPSB2 | ALDH1A1 355/4885SMN1; SMN2 2085/4885L3MBTL1 4389/4885 |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | TNFSF11, CD14, TNFRSF1A | ALDH1A1 2750/4885SMN1; SMN2 1728/4885L3MBTL1 1566/4885 |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | ALDH1A1 4582/4885SMN1; SMN2 2398/4885L3MBTL1 1814/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | ALDH1A1 1305/4885SMN1; SMN2 2159/4885L3MBTL1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.